Autoimmune Hepatitis: Symptoms, Diagnosis and Treatment

Autoimmune hepatitis can raise difficult questions about blood tests, medicines, everyday symptoms and the future. This guide explains how clinicians bring those pieces together, what treatment is trying to achieve, and which questions deserve a personal discussion with a liver specialist. It is general educational information, not a diagnosis or an individual treatment plan.

Information checked October 15, 2026. Consult a qualified healthcare professional about your circumstances and read our medical disclaimer.

Seek urgent medical help for new jaundice or rapidly worsening illness. Do not wait for a routine appointment. ²

What is autoimmune hepatitis?

Autoimmune hepatitis, often shortened to AIH, is an inflammatory liver disease in which the immune system attacks the liver. Its course varies: someone may feel well when abnormal tests are discovered, develop a long period of illness, or become severely unwell over a short time. Without effective control, inflammation can lead to advanced scarring and liver failure. Immune-suppressing treatment has transformed care, but treatment also brings risks and usually requires ongoing supervision. The diagnosis does not describe how much damage a particular person already has. That requires a separate assessment of disease activity, liver function and scarring. A liver specialist therefore needs more than the name of the condition to explain someone’s outlook or the purpose of each part of their care. ³

The word hepatitis means liver inflammation; it does not identify its cause. Autoimmune hepatitis is not contagious, so another person cannot catch it through ordinary contact. Viral hepatitis, alcohol-related hepatitis and autoimmune hepatitis are different conditions, even though some symptoms overlap. A person who sees hepatitis on a medical record should ask which cause has been established rather than assuming an infection. This distinction also matters when reading treatment information: medicines aimed at a virus address a different problem from medicines that reduce an autoimmune attack. Families do not need to treat the diagnosis as evidence that sharing a meal or spending time together is unsafe. ²

Who can develop it, and why?

Population studies help explain who is diagnosed, but they cannot tell an individual why they developed the disease. An English study covering 1997–2015 found approximately two new diagnoses per 100,000 people each year. Diagnoses were more frequent among women and at older ages. These findings challenge the idea that autoimmune hepatitis belongs only to one narrow age group. They are also historical observations from one country, not a worldwide rate for today. The researchers used routinely collected health records, so the results reflect both the disease and the way cases were recognized and recorded. A demographic pattern is a reason for awareness, not a rule that excludes someone outside the most commonly affected group. ⁶

Researchers have not identified a single cause of autoimmune hepatitis. Inherited susceptibility and environmental influences are thought to interact, but a diagnosis rarely comes with a definite explanation of the trigger. Symptoms can include fatigue, aching joints, nausea, poor appetite, discomfort over the liver, jaundice, dark urine and pale stools. Some people have no symptoms at diagnosis. Medicines can also cause a liver injury that resembles autoimmune hepatitis, making a complete medication history important. These possibilities should be investigated without blaming the person for their illness or assuming that every new symptom must come from the liver. The same symptom can have several explanations, and an absence of symptoms does not reliably establish that there is no liver inflammation. ¹

What happened to type 1 and type 2?

Older information often divides autoimmune hepatitis into type 1 and type 2 according to antibody patterns. Those terms may still appear in records, especially in pediatric care. The 2025 European Association for the Study of the Liver guideline does not recommend this antibody-based subclassification for adults because it is not sufficiently useful for clinical decisions. Ask what an antibody result means in the context of the whole assessment rather than treating a numbered type as a severity rating. ⁵

How autoimmune hepatitis is diagnosed

Diagnosis usually includes liver biopsy, with specialist judgment about timing if urgent treatment or procedural risks change the sequence. Other explanations for inflammation must also be considered. The 2025 British Society of Gastroenterology guideline recommends liver imaging and appropriate infection testing, alongside assessment for conditions such as drug-induced liver injury, Wilson’s disease and metabolic dysfunction-associated steatotic liver disease. The possibilities differ between a sudden severe illness and a slowly discovered abnormal result. Some conditions can coexist, so finding fat in the liver does not automatically settle every diagnostic question. Clinicians also consider bile-duct disorders, including primary biliary cholangitis and primary sclerosing cholangitis, when the pattern suggests them. This is why the evaluation can involve several visits and different kinds of test rather than a single autoimmune screening panel. ⁴

Blood tests answer different questions

A liver blood panel is a collection of measurements, not one overall liver score. ALT and AST are enzymes used when assessing possible injury. Albumin is a protein made by the liver, bilirubin is a waste product the liver helps remove, and clotting tests examine another aspect of liver function. Clinicians compare patterns across results and interpret them alongside symptoms, medical history and medicines. An abnormal result alone usually cannot identify a specific disease. Nor do results from different laboratories always use identical reference ranges. When discussing a trend, keep the actual number, its units, the laboratory’s range and the collection date together. Ask which measurements your team is using to assess inflammation and which are being used for other parts of the evaluation. ⁷

Autoantibodies and immunoglobulin G, usually called IgG, are important pieces of the investigation. The simplified diagnostic criteria developed by the International Autoimmune Hepatitis Group combine autoantibodies, IgG, liver histology and exclusion of viral hepatitis. The criteria were developed and tested using patients from multiple centers, rather than depending on one laboratory result. Their structure illustrates an important principle: a positive antibody result gains meaning from the surrounding evidence. A score also has limitations and should be used by clinicians who understand the testing and the clinical setting. It is not a reliable home checklist for turning a positive antinuclear antibody result into a diagnosis, and it should not replace a specialist’s assessment of a difficult or atypical presentation. ⁸

Normal IgG does not completely rule out autoimmune hepatitis. In a European multicenter study of 1,318 people with the disease, about one in ten had IgG within the normal range at presentation. Their liver findings and response to treatment were broadly comparable with those of people whose IgG was elevated. That result does not mean everyone with normal IgG and an abnormal liver test has autoimmune hepatitis. It means a normal result cannot do all the work of excluding it when other evidence remains concerning. A clinician may need to revisit the complete picture, including biopsy findings and alternative diagnoses. The study describes a selected clinical population, so its percentage should not be interpreted as the chance that any particular person has the condition. ⁹

Why a liver biopsy may matter

A liver biopsy collects a small tissue sample for examination under a microscope. It can help clarify an uncertain cause of liver disease and assess injury or scarring that blood tests cannot directly show. Different biopsy approaches are available, and the choice depends partly on factors such as bleeding risk or fluid in the abdomen. A biopsy is not risk-free: pain can occur, and bleeding is an important possible complication. Before the procedure, ask why it is being recommended, which approach is planned, how your medicines will be reviewed, and what aftercare instructions apply. Follow the procedural team’s instructions rather than changing medicines yourself. Understanding the reason for the test is separate from consenting to it; both deserve an opportunity for questions. ¹⁰

A liver stiffness scan, often called transient elastography, can help assess fibrosis, but its interpretation depends on timing. Research in autoimmune hepatitis found that active inflammation affected stiffness measurements early in treatment. After inflammation had been treated for a period, the scan performed better as an assessment of scarring. A high stiffness result near diagnosis therefore does not automatically mean the same thing as a similar result during stable follow-up. Ask whether the scan was taken during active inflammation, what question it was intended to answer, and whether comparison with another measurement is appropriate. The scan and a biopsy supply different kinds of information. A scan result should not be used alone to declare that treatment has failed or that established cirrhosis has disappeared. ¹¹

Treatment: controlling inflammation while limiting harm

Treatment decisions consider disease severity, scarring, other illnesses, previous adverse effects and reproductive plans. For adults, the 2025 EASL guideline includes prednisolone or prednisone with either azathioprine or mycophenolate mofetil as initial treatment options. It no longer recommends budesonide as first-line treatment, and budesonide is contraindicated in cirrhosis. This differs from some older guidance readers may still find online. These recommendations are a framework for specialist decisions, not instructions to exchange medicines. Someone already taking a medicine mentioned in older advice should discuss its purpose and suitability with their own team rather than making an abrupt change after reading an updated article. ⁵

Guidelines differ: the 2025 British Society of Gastroenterology guidance still allows budesonide for selected adults without cirrhosis when steroid-related appearance changes are a major concern. It generally favors a corticosteroid with azathioprine initially. Your specialist can explain how the applicable guidance fits your circumstances. ⁴

One reason the treatment discussion has evolved is the CAMARO randomized trial, published in 2024. Seventy previously untreated adults received either mycophenolate mofetil or azathioprine, each combined with prednisolone. At 24 weeks, the trial’s primary biochemical-remission outcome was achieved more often in the mycophenolate group, and fewer participants stopped that medicine because of adverse effects. The study was relatively small and open-label, meaning participants and clinicians knew which treatment was being given. It compared specific trial strategies over a defined period; it did not establish that one medicine is best for every patient or settle every long-term safety question. The useful message is that there are evidence-based choices to discuss, with the balance of benefits and harms considered for the individual. ¹²

Corticosteroid safety deserves a plan

Prednisone labeling describes several risks that become relevant during treatment, including infection susceptibility, changes in blood glucose, mood or sleep disturbance, bone loss and eye problems. Risk depends partly on exposure and on the person’s circumstances. Corticosteroids can also suppress the body’s own adrenal hormone production, which is one reason an abrupt unsupervised stop can be dangerous. Report troublesome effects instead of quietly tolerating them or changing the prescription alone. Ask how the team will monitor the problems most relevant to you and whom to contact between visits. Seek medical advice promptly if you develop fever or other signs of infection while taking corticosteroids. Side-effect monitoring is part of making treatment sustainable, rather than evidence that the benefits of controlling liver inflammation have been forgotten. ¹³

Azathioprine can affect bone-marrow production of blood cells, and its labeling includes warnings about serious infection and certain cancers. Differences in the TPMT and NUDT15 pathways can increase susceptibility to severe toxicity. Depending on the clinical setting, clinicians may use enzyme or genetic testing, but such testing does not replace ongoing blood counts. A reassuring pretreatment result is not a lifetime guarantee against adverse effects. A medication review also matters because other drugs can interact with azathioprine; allopurinol and febuxostat are notable examples. Give the prescriber and pharmacist an up-to-date list, including medicines from other specialists. If a new medicine is proposed, make sure the professional prescribing it knows about the existing treatment before the first dose is taken. ¹⁴

The practical side of treatment should be made explicit before a prescription becomes a daily routine. Ask who issues refills, which clinic receives blood-test results, how you will hear about them, and what happens if an appointment is delayed. Keep the current written instructions separate from superseded versions, and note the date of any change made by the prescriber. If cost, transport, swallowing difficulties or pharmacy supply creates a barrier, tell the team while there is still time to solve it. A useful care conversation includes the real circumstances in which the plan has to work. Bringing a list of these obstacles is more helpful than leaving the clinician to assume that every missed step was a deliberate choice.

What remission and follow-up really mean

Treatment response has several meanings. An international consensus on autoimmune hepatitis outcomes distinguishes biochemical response, insufficient response, non-response, histological remission and intolerance. The biochemical target is normalization of ALT, AST and IgG; histological remission concerns inflammation seen in liver tissue. Intolerance describes a treatment-related problem that prevents a medicine being continued, rather than proof that the medicine could not control the disease. These distinctions help explain why two people may need different next steps despite both hearing that their treatment is not going as planned. Ask which outcome is being assessed, what information supports the conclusion and what will be checked next. The terms are useful for communication, but a research definition is not a personal deadline for waiting through worsening symptoms or a reason to adjust treatment independently. ¹⁵

Blood tests remain valuable, but their reassurance has limits in some circumstances. A study of autoimmune hepatitis with cirrhosis found that normal ALT and IgG did not reliably exclude continuing inflammation in liver biopsies. This finding is especially relevant to people with established cirrhosis; it should not be generalized into a claim that normal tests are meaningless for everyone. The study also does not mean every stable patient needs repeated biopsy. Instead, it helps explain why a specialist may consider additional information when the clinical picture and the blood results do not agree. Ask how your stage of liver disease changes the interpretation of apparently normal results, and what would justify further investigation in your particular situation. ¹⁶

Why stopping treatment requires careful selection

Feeling better and having normal tests do not necessarily mean treatment can end permanently. In a Dutch retrospective study, many patients who attempted withdrawal after at least two years of remission later needed treatment again. By three years after withdrawal, the proportion requiring retreatment had reached about four in five. The exact risk varies with patient selection and the definition used, so this historical study cannot predict one person’s future. It does show why a supervised withdrawal attempt is a different decision from simply running out of tablets. If withdrawal is being considered, ask what makes it reasonable, what monitoring will continue and how a recurrence would be handled. Continued follow-up remains important even when a carefully selected patient is no longer taking medication. ¹⁷

A useful results record should tell a short, accurate story rather than become a collection of unexplained numbers. Store copies of clinic letters, the biopsy report if available, imaging reports and the current medicine list in one place. Mark which questions have already been answered and which remain open. When transferring care, ask the previous clinic how records will reach the next team and whether you need to supply anything yourself. Record the name of the clinician responsible for follow-up and the expected date of the next contact. If an expected result or appointment does not arrive, ask the service how to trace it. Clear ownership of these small steps reduces the chance of assuming that someone else has already arranged them.

Preventing avoidable problems during treatment

Vaccines and infection planning

Immune-suppressing treatment changes vaccine planning, but it does not mean every vaccine is unsafe. CDC guidance explains that non-live vaccines are generally safe in people with altered immune function, although the response may be weaker. Live vaccines require particular caution because their safety depends on the degree and cause of immunosuppression. The exact medicine, treatment intensity and timing all matter. Bring your vaccination record to the treating team rather than accepting a blanket rule from an online discussion. Ask which vaccines are suitable now, whether any would be better timed before planned treatment, and whether special advice is needed before travel. Vaccine decisions should be coordinated with the team managing the liver disease rather than made by stopping immune-suppressing treatment to create a vaccination window. ¹⁸

Protection against hepatitis A and hepatitis B is a separate issue from the cause of autoimmune hepatitis. Current US adult vaccination guidance includes autoimmune hepatitis among chronic liver diseases relevant to these recommendations. A vaccine against a hepatitis virus does not treat the autoimmune condition, but it may address an additional preventable infection risk. The appropriate plan depends on previous doses, documented immunity and other individual factors. Ask the clinic to reconcile old records and explain what is still needed. People outside the United States should use their own national recommendations with their healthcare team, because schedules, eligibility and available products can differ. Keep a copy of any newly completed vaccinations with the rest of your care record. ¹⁹

Bone health is more than a supplement

Long-term care may include assessment of fracture risk and bone density, particularly when medicines or other factors increase that risk. NIAMS guidance on osteoporosis describes several complementary approaches: adequate calcium and vitamin D, appropriate physical activity, fall prevention and medicines when indicated. No single supplement guarantees protection against fractures. A bone-health discussion should consider diet, previous fractures, mobility, other conditions and any existing treatment. Ask whether a bone-density scan is appropriate and what practical changes are suitable for your abilities. If balance or strength is a concern, request advice before beginning an unfamiliar exercise program. Keep this plan connected to the liver treatment plan so different clinicians know what has already been assessed and prescribed. ²⁰

Pregnancy, children and other important circumstances

Pregnancy planning should begin with the liver team before conception whenever possible. AASLD reproductive guidance advises aiming for well-controlled autoimmune hepatitis on a stable regimen and emphasizes that maintaining control matters during pregnancy. Some commonly used treatments, including azathioprine and certain corticosteroids, may be continued after an individualized discussion; pregnancy does not automatically mean stopping all medicines. Mycophenolic acid products are a major exception because of their reproductive risks. Monitoring also matters after delivery, when flares can occur. Ask the hepatology and maternity teams to agree on who will arrange liver tests, review symptoms and discuss breastfeeding. The plan should extend into the postpartum months, when attention can understandably shift almost entirely to the baby. ²¹

Mycophenolate mofetil has a boxed warning about pregnancy loss and serious birth defects. Its prescribing information calls for pregnancy testing and effective pregnancy prevention, with specific advice that can also apply to male patients and their partners. The choice of contraception needs professional guidance; not every acceptable method requires the same combination of precautions. Anyone planning pregnancy while taking mycophenolate should contact the prescribing team well in advance to discuss a safer treatment strategy and the timing of any change. If pregnancy occurs or is suspected, contact the team urgently. Do not improvise a medication switch or assume that suddenly stopping treatment is the safest response. Drug labeling is a safety resource, and it is not evidence that every use of a medicine is a licensed indication. ²²

Children and adolescents need pediatric liver expertise because the diagnostic approach and practical priorities are not identical to those in adults. The ESPGHAN position statement discusses autoimmune hepatitis alongside autoimmune sclerosing cholangitis, a related condition in which bile-duct assessment can be important. Adult diagnostic scores should not simply be applied to a child without appropriate interpretation. Long-term care also has to fit school, growth, family routines and the gradual move toward independent self-management. A teenager should have opportunities to ask questions in language they understand, while caregivers remain involved as appropriate. When transition to adult services approaches, ask for a named receiving team, an accessible treatment summary and a clear plan for prescriptions and monitoring during the handover. ²³

Cirrhosis, cancer surveillance and transplantation

Cirrhosis changes the scope of care because it can create complications beyond the original inflammation. These include fluid accumulation, enlarged veins that may bleed, and confusion related to hepatic encephalopathy. Treatment is directed at the particular complication as well as its underlying cause. A person with cirrhosis should know which symptoms require urgent help and how to reach the care team. New swelling or changes in thinking deserve medical attention, while vomiting blood or passing black or bloody stools requires immediate hospital assessment. Do not assume a symptom is an expected inconvenience of chronic liver disease. Ask for clear written instructions and share them with a trusted person if you want help recognizing a serious change. ²⁴

For appropriate people with cirrhosis, liver-cancer surveillance aims to find cancer before it causes symptoms. AASLD guidance generally recommends ultrasound and an alpha-fetoprotein blood test approximately every six months for eligible at-risk patients. Eligibility and the best imaging approach depend on clinical circumstances, including whether the person could benefit from cancer treatment or transplantation. Surveillance is not the same as diagnosing cancer, and a normal check does not remove the need for the next scheduled one. An unusual finding may require a different scan or closer follow-up. Ask whether surveillance applies to you, which tests are planned and who will recall you. This is distinct from routine blood tests used to follow autoimmune inflammation, so one appointment may not cover both tasks. ²⁵

Liver transplantation may be considered when liver failure or other serious liver disease cannot be managed adequately by other means. It replaces a diseased liver with a donor liver or part of a living donor’s liver. Referral for transplant assessment is an evaluation process, not a guarantee that surgery will happen or an indication that every person with autoimmune hepatitis will eventually need it. A transplant team considers medical suitability and the practical requirements of care. If referral is discussed, ask why it is being considered now, what the assessment involves and how ongoing treatment will be coordinated. It can help to take a trusted person to appointments and write down questions about the process, travel, support and communication with the existing liver team. ²⁶

For background on related liver topics, see our guides to liver failure and hepatitis C treatments. Use your clinician’s confirmed diagnosis to decide which information applies.

Living with autoimmune hepatitis

Fatigue and quality of life deserve attention

Daily wellbeing is not fully captured by laboratory targets. A study comparing 140 people with autoimmune hepatitis with a control group found substantial burdens involving fatigue, anxiety, depression and health-related quality of life. Its findings describe a group, not an inevitable experience for every patient, and they do not prove that any single symptom has one cause. They do support making room for these concerns during routine care. Explain how a problem changes ordinary activities rather than only rating it as mild or severe. For example, describe whether tiredness prevents shopping, concentration, work or time with family. Asking for assessment of persistent symptoms and emotional distress is a legitimate part of care even when the conversation also includes encouraging blood-test results. ²⁷

Qualitative research with autoimmune hepatitis support-group participants found that symptoms and treatment effects could influence work, relationships, social activities and communication with clinicians. Because participants were recruited through support groups, the findings should not be treated as a population survey. Their experiences nevertheless highlight questions worth asking: what is hardest to manage, what has changed in daily life, and what support is missing? A short symptom diary can help organize that conversation, but it should not become a self-diagnosis tool. Note when a problem occurs and what it prevents you from doing. Discuss practical adjustments with the relevant people while deciding for yourself how much personal medical information you want to disclose. ²⁸

Food, alcohol and supplements

A varied, balanced eating pattern is a more useful starting point than a highly restrictive diet adopted solely because it carries an autoimmune label. NHS patient information recommends balanced nutrition and avoiding alcohol with autoimmune hepatitis. Ask the liver team whether your current liver condition creates particular dietary needs and whether a dietitian would help. If appetite, nausea, weight changes or another diagnosed condition makes eating difficult, explain that before cutting out major food groups. Keep the discussion practical: what foods you can obtain, what you can afford, what you tolerate and what you can prepare. Dietary advice should fit those circumstances. A plan that cannot be followed in everyday life needs adjustment rather than blame, and nutrition questions should be discussed alongside the medical treatment plan. ³⁰

Herbal products and supplements should be included in the medication conversation. NIH’s LiverTox resource documents liver injury linked to prescription medicines, nonprescription products and selected supplements. Natural origin does not establish that a product is harmless to the liver. Bring the actual ingredient list or a clear photograph of the packaging when asking about a product, because a brand name alone may not identify everything it contains. Include powders, teas, bodybuilding products and items marketed for cleansing or liver support. A clinician or pharmacist can help assess the particular product and its relationship to the rest of the treatment plan. Do not substitute a supplement for prescribed treatment or assume that a product’s marketing claims have been tested in people with autoimmune hepatitis. ²⁹

Making the next appointment useful

Choose the two or three questions that matter most before the visit. One may concern the diagnosis, another the treatment burden, and another a practical obstacle such as travel or prescription access. Bring the current medicine list and any new reports, but do not feel obliged to produce a perfect medical archive. Ask the clinician to explain unfamiliar terms and to summarize the next step in everyday language. Before leaving, check what you are expected to arrange, what the service will arrange and when you should hear back. If you want a family member involved, decide what role would help: listening, taking notes or assisting with follow-up. The aim is a shared, understandable plan that you can refer to after the appointment.

Frequently asked questions

Can autoimmune hepatitis be caught from someone else?

No. Autoimmune hepatitis is not contagious. The word hepatitis describes liver inflammation, and different causes need different assessments. ²

Can autoimmune hepatitis occur without symptoms?

Yes. Some people have no symptoms when abnormal blood tests lead to the diagnosis. Symptoms alone cannot show how active the disease is. ¹

Can I stop treatment myself?

No. Discuss any change with your liver specialist. A supervised withdrawal requires careful selection and continuing follow-up. ¹⁷

Educational background video retained from the original article; not assessed in full. Its explanations may differ from current guidance. Discuss diagnosis and treatment decisions with a qualified healthcare professional.